Skip to Content
Merck
HomeCampaignsRequest Information

Request for More Information Today on our Viral Vector Upstream Platforms

Researcher wearing safety gear in a laboratory working with a substance behind a protective barrierwearing a lab coat, gloves, facemask, protective glasses working with a substance behind a protective shield.

Upstream platforms for both AAV and Lentivirus vector production simplify decision-making, allowing you to confidently transition swiftly from process development to larger scale GMP Production. The following upstream platforms offered are:

  • VirusExpress® Lentiviral Platform for Lentiviral Vector-Based Cell Therapies
  • VirusExpress ® AAV Platform for HEK293 Cells Based  Gene Therapies
  • SF-RVN® Platform for Insect Cell Based Gene Therapies

In addition, multiple strains of Human Embryo Kidney (HEK)293 cell lines are frequently employed in AAV production, each with distinct preferences. To expedite process refinement, our new cell culture medium, Cellvento® 4HEK Medium has been created, fostering robust cell growth and virus production across various HEK293 strains. 

To refer back to our product page, please click here.

For more information on any of our Viral Vector Upstream Platforms, or our chemically defined, animal component-free Cellvento® 4HEK Medium, please complete the webform below and a technical expert will be in touch with you soon.

Fields indicated by a are mandatory.

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?